Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
| Autor: | Galle, Peter R *, Finn, Richard S, Qin, Shukui, Ikeda, Masafumi, Zhu, Andrew X, Kim, Tae-You, Kudo, Masatoshi, Breder, Valeriy, Merle, Philippe, Kaseb, Ahmed, Li, Daneng, Mulla, Sohail, Verret, Wendy, Xu, Derek-Zhen, Hernandez, Sairy, Ding, Beiying, Liu, Juan, Huang, Chen, Lim, Ho Yeong, Cheng, Ann-Lii, Ducreux, Michel |
|---|---|
| Zdroj: | In The Lancet Oncology July 2021 22(7):991-1001 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|